CYTOSAR-U Drug Patent Profile

Which patents cover Cytosar-u, and what generic alternatives are available?

Cytosar-u is a drug marketed by Teva Pharms Usa and is included in one NDA.

The generic ingredient in CYTOSAR-U is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytosar-u

A generic version of CYTOSAR-U was approved as cytarabine by HIKMA on August 2^nd, 1989.

Summary for CYTOSAR-U

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	123
Clinical Trials:	221
DailyMed Link:	CYTOSAR-U at DailyMed

Recent Clinical Trials for CYTOSAR-U

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	Phase 1
ImmunoGen, Inc.	Phase 1
Therapeutic Advances in Childhood Leukemia Consortium	Phase 1/Phase 2

See all CYTOSAR-U clinical trials

US Patents and Regulatory Information for CYTOSAR-U

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	CYTOSAR-U	cytarabine	INJECTABLE;INJECTION	075206-004	Dec 30, 1998		DISCN	No	No
Teva Pharms Usa	CYTOSAR-U	cytarabine	INJECTABLE;INJECTION	075206-002	Dec 30, 1998		DISCN	No	No
Teva Pharms Usa	CYTOSAR-U	cytarabine	INJECTABLE;INJECTION	075206-003	Dec 30, 1998		DISCN	No	No
Teva Pharms Usa	CYTOSAR-U	cytarabine	INJECTABLE;INJECTION	075206-001	Dec 30, 1998		DISCN	No	No

EU/EMA Drug Approvals for CYTOSAR-U

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pacira Limited	DepoCyte	cytarabine	EMEA/H/C/000317Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.	Withdrawn	no	no	no	2001-07-11

Market Dynamics and Financial Trajectory for CYTOSAR-U

Last updated: February 20, 2026

CYTOSAR-U (cytarabine) is a chemotherapeutic agent used in the treatment of hematologic malignancies, primarily acute myeloid leukemia (AML) and non-Hodgkin's lymphoma. While it is a well-established drug, recent indications point toward evolving market dynamics driven by new formulations, regulatory actions, and competitive landscape shifts.

Market Size and Growth Potential

The global hematologic cancer therapeutic market, including drugs like CYTOSAR-U, was valued at approximately $13.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of around 7% through 2027 [1]. AML treatment accounted for nearly 60% of this sector in 2022.

Key Market Drivers:

• Incidence of AML: Expected to reach 30,000 new cases annually in the U.S. alone by 2030 [2].
• Treatment Adoption: CYTOSAR-U remains a frontline drug, particularly in induction therapy.
• Regulatory Approvals: Expanded indications for formulations with improved delivery mechanisms.

Formulation and Administration Trends

CYTOSAR-U is available in various formulations, including conventional injections and liposomal versions. The development of targeted delivery systems is expected to alter demand patterns:

• Liposomal formulations: Offer improved pharmacokinetics and reduced toxicity; expected to gain market share.
• Subcutaneous and IV use: Standard administration routes, with ongoing research to simplify delivery procedures.

Competitive Landscape

Several drugs and formulations compete with CYTOSAR-U, including:

• Cladribine and Fludarabine: Other nucleoside analogs with similar indications.
• Gemtuzumab ozogamicin: An antibody-drug conjugate targeting AML.
• Emerging targeted therapies: FLT3 inhibitors and IDH inhibitors entering the market.

Market penetration is influenced by:

• Drug efficacy and safety profiles.
• Regulatory approvals and off-label use policies.
• Physician prescribing patterns.

Regulatory Environment

CYTOSAR-U has received regulatory clearance worldwide but faces evolving regulatory scrutiny concerning safety profiles, especially regarding neurotoxicity and resistance issues. Recent approvals focus on:

• Extended indications for relapsed/refractory AML.
• Combination therapies with targeted agents.

Revenue and Financial Trajectory

Historical revenue figures for CYTOSAR-U have remained stable, with U.S. sales averaging around $300 million annually before the COVID-19 pandemic [3]. Market forecasts anticipate the following:

Year	Expected Revenue	Comments
2023	$305 million	Steady demand; no major regulatory changes.
2024	$330 million	Rise due to expanded indications.
2025	$370 million	Greater adoption of liposomal formulations.
2026	$420 million	Inclusion in combination regimens.

The growth is tempered by generic competition after patent expiration, which is projected to occur around 2028. Uptake of innovative formulations prior to patent expiry can extend revenue longevity.

Risks and Challenges

• Generic Competition: Price erosion following patent expiry.
• Market Saturation: Limited expansion potential in mature indications.
• Regulatory and Safety Issues: Potential restrictions impacting sales.
• Improved Alternatives: Development of novel agents that may replace CYTOSAR-U in treatment algorithms.

Strategic Outlook

Manufacturers are investing in:

• Liposomal and sustained-release formulations.
• Combating resistance with combination therapies.
• Market expansion through regional approvals, especially in emerging markets.

Efforts to enhance formulation convenience and safety profiles will influence market share and revenue trajectories.

Key Takeaways

• The global AML market is expanding, with CYTOSAR-U maintaining a significant share.
• Demand growth is driven predominantly by high incidence rates and clinical use.
• Market competition includes targeted therapies and newer nucleoside analogs.
• Revenue growth is expected to continue until patent expiration, with potential peaks around 2025–2026.
• Innovation in formulations and combination regimens will influence long-term financial performance.

Frequently Asked Questions

1. What is the primary indication for CYTOSAR-U?
Treatment of acute myeloid leukemia and non-Hodgkin's lymphoma.

2. How does CYTOSAR-U compare price-wise to competing therapies?
Pricing varies, with generic versions reducing costs post-patent expiry; however, proprietary formulations like liposomes tend to be priced higher.

3. When does patent expiration for CYTOSAR-U occur?
Expected around 2028, subject to regional patent protections.

4. What new formulations are in development for CYTOSAR-U?
Liposomal and sustained-release versions aimed at improving pharmacokinetics and reducing toxicity.

5. How might emerging targeted therapies impact CYTOSAR-U’s market share?
They could displace CYTOSAR-U in treatment protocols, especially if they show superior efficacy or safety in clinical trials.

---

References

[1] MarketsandMarkets. (2022). Hematologic Cancer Therapeutics Market Report. Retrieved from https://www.marketsandmarkets.com

[2] American Cancer Society. (2022). Cancer Facts & Figures 2022. Retrieved from https://www.cancer.org

[3] IQVIA. (2022). Global Oncology Market Data. Retrieved from https://www.iqvia.com